{"disease":{"id":"neuroendocrine-tumors-of-pancreatic-origin","name":"neuroendocrine tumors of pancreatic origin"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01177397","title":"Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":226,"lead_sponsor_name":"Celgene","has_results":true}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}